Fexofenadine Pharmacokinetics Are Associated with a Polymorphism of the SLCO1B1 Gene (encoding OATP1B1)

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2005 Apr 22

PMID 15842561

Citations 40

Authors

Mikko Niemi

Kari T Kivisto

Ute Hofmann

Matthias Schwab

Michel Eichelbaum

Martin F Fromm

Affiliations

Soon will be listed here.

Citing Articles

Ultra-Sensitive Quantification of Coproporphyrin-I and -III in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled to Quadrupole Time-of-Flight Mass Spectrometry.

Negami J, Suzuki Y, Sato H, Toyama D, Tanaka R, Ono H ACS Omega. 2024; 9(47):47135-47144.

PMID: 39619527 PMC: 11603277. DOI: 10.1021/acsomega.4c07566.

Quantitative assessment of the relevance of organic-anion-transporting-polypeptide 1B1 and 2B1 polymorphisms in fexofenadine pharmacokinetic variants via pharmacometrics.

Jang J, Jeong S, Lee Y J Pharm Anal. 2023; 13(6):660-672.

PMID: 37440913 PMC: 10334346. DOI: 10.1016/j.jpha.2023.04.001.

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity.

Rausch M, Samodelov S, Visentin M, Kullak-Ublick G Int J Mol Sci. 2022; 23(22).

PMID: 36430444 PMC: 9695947. DOI: 10.3390/ijms232213967.

Frequency of functional exonic single-nucleotide polymorphisms and haplotype distribution in the SLCO1B1 gene across genetic ancestry groups in the Qatari population.

Dashti M, Al-Matrouk A, Channanath A, Al-Mulla F, Thanaraj T Sci Rep. 2022; 12(1):14858.

PMID: 36050458 PMC: 9437070. DOI: 10.1038/s41598-022-19318-x.

Exposure of Fexofenadine, but Not Pseudoephedrine, Is Markedly Decreased by Green Tea Extract in Healthy Volunteers.

Misaka S, Ono Y, Taudte R, Hoier E, Ogata H, Ono T Clin Pharmacol Ther. 2022; 112(3):627-634.

PMID: 35678032 PMC: 9540489. DOI: 10.1002/cpt.2682.

References

Cvetkovic M, Leake B, Fromm M, Wilkinson G, Kim R . OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999; 27(8):866-71. View

Tamai I, Nezu J, Uchino H, Sai Y, Oku A, SHIMANE M . Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000; 273(1):251-60. DOI: 10.1006/bbrc.2000.2922. View

Niemi M, Schaeffeler E, Lang T, Fromm M, Neuvonen M, Kyrklund C . High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004; 14(7):429-40. DOI: 10.1097/01.fpc.0000114750.08559.32. View

Marzolini C, Tirona R, Kim R . Pharmacogenomics of the OATP and OAT families. Pharmacogenomics. 2004; 5(3):273-82. DOI: 10.1517/phgs.5.3.273.29831. View

Marzolini C, Paus E, Buclin T, Kim R . Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004; 75(1):13-33. DOI: 10.1016/j.clpt.2003.09.012. View

Hatanaka T . Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2001; 39(6):397-412. DOI: 10.2165/00003088-200039060-00002. View

Kim R, Leake B, Choo E, Dresser G, Kubba S, Schwarz U . Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001; 70(2):189-99. DOI: 10.1067/mcp.2001.117412. View

Tirona R, Leake B, Merino G, Kim R . Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001; 276(38):35669-75. DOI: 10.1074/jbc.M103792200. View

Dresser G, Bailey D, Leake B, Schwarz U, Dawson P, Freeman D . Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002; 71(1):11-20. DOI: 10.1067/mcp.2002.121152. View

10.

Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U . MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 2002; 53(5):526-34. PMC: 1874364. DOI: 10.1046/j.1365-2125.2002.01591.x. View

11.

Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C . Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther. 2002; 72(5):584-94. DOI: 10.1067/mcp.2002.129196. View

12.

Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I . Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003; 306(2):703-8. DOI: 10.1124/jpet.103.051300. View

13.

Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang W . A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999; 274(52):37161-8. DOI: 10.1074/jbc.274.52.37161. View

14.

Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I . Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2003; 308(2):438-45. DOI: 10.1124/jpet.103.060194. View

15.

Simons F, Simons K . Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999; 36(5):329-52. DOI: 10.2165/00003088-199936050-00003. View